Distilled business knowledge from the frontline experts.
Portfolio & Planning Manager
GlaxoSmithKline
- Why oncology market access models must evolve
The proliferation of stakeholders makes oncology market access increasingly complex—and successful models increasingly essential. Peter Mansell reports.
9:59am, 7th Sep 2010 - Comprehensive strategies for market access
Alan Crofts outlines the flexible market access strategies needed to address the needs of clinical and non-clinical decision makers.
9:51am, 7th Sep 2010 - Market access: Risk sharing and alternative pricing schemes
Shared-risk agreements can represent uncertain rewards for drug makers and payers. What you need to know before entering into one.
2:33pm, 10th Aug 2010
Who We Are
Welcome to the first eyeforpharma Market Access US conference. I'm Maria and I will be organising the event this year - and so far I am having good fun. A particular highlight has been discovering this key area and talking to key people in the industry to identify the issues and listen to the concerns and comments..
The enthusiasm of everyone during my research as well as the willingness to get involved in the event to create a solid community around Market Access has been something I haven't come across in my 3 years experience as a Conference Organiser.
My work related passion are US events, especially all eMarketing and digital events, as I am a bit of a techy girl. I have also looked into emerging markets recently and organised a SFE conference in the Middle East.
Generally I would say I enjoy travelling very much and my job has given me ample opportunities to do so, which is great.
I have thoroughly enjoyed working on putting the programme together so whether it will be getting in touch with a travel destination suggestion or a speaker recommendation please do, I'd love to hear from you!
Maria RelakiVP US
eyeforpharma
T: +44 207 375 7575
E: mrelaki@eyeforpharma.com
W: www.eyeforpharma.com/mausa
